Key result
ACEi/ARBs link to improved 1-year survival over beta-blockers in Takotsubo syndrome, despite ~6% annual mortality.
Why the study?
There is a gap in evidence and a lack of randomized, adequately powered studies evaluating the clinical effectiveness of therapeutic approaches for Takotsubo syndrome.
This review highlights that Takotsubo syndrome carries substantial acute and long-term morbidity and mortality comparable to acute coronary syndromes, requiring tailored supportive acute care (avoiding catecholamines) and long-term ACEi/ARB therapy alongside multidisciplinary comorbidity management.
Answers are grounded in this paper and cite their sources.
May support ACEi/ARB preference post-Takotsubo; leaves open randomized confirmation of survival benefit.
Takotsubo syndrome (TTS) represents a form of acute heart failure featured by reversible left ventricular systolic dysfunction. The management during the acute phase is mainly performed with supportive pharmacological (diuretics, ACE-inhibitors/angiotensin-receptor blockers (ARBs), anticoagulants, antiarrhythmics, non-catecholamine inotropics (levosimendan), and non-pharmacological (mechanical circulatory and respiratory support) therapy, due to the wide clinical presentation and course of the disease. However, there is a gap in evidence and there are no randomized and adequately powered studies on clinical effectiveness of therapeutic approaches. Some evidence supports the use ACE-inhibitors/ARBs at long-term. A tailored approach based on cardiovascular and non-cardiovascular risk factors is strongly suggested for long-term management. The urgent need for evidence-based treatment approaches is also reflected by the prognosis following TTS. The acute phase of the disease can be accompanied by various cardiovascular complications. In addition, long term outcome of TTS patients is also related to non-cardiovascular comorbidities. Physical triggers such as hypoxia and acute neurological disorders in TTS are associated with a poor outcome.
No takes yet. Share an insight, caveat, or question.
Santoro et al. (2021) conducted a review in Takotsubo syndrome (TTS). Supportive pharmacological (diuretics, ACEi/ARBs, anticoagulants, antiarrhythmics, levosimendan) and non-pharmacological (mechanical circulatory and respiratory support) therapy was evaluated on Short- and long-term mortality, major adverse cardiac and cerebrovascular events (MACCE), and TTS recurrence. Takotsubo syndrome carries a 5.6% per patient-year long-term mortality rate and 9.9% per patient-year MACCE rate, with observational evidence supporting ACEi/ARBs over beta-blockers for 1-year survival.
Synapse has enriched 10 related papers. Consider them for comparative context: